Multiple regression analysis
| Factor . | GRFS* . | CRFS* . | aGVHD III-IV† . | cGVHD . | Relapse‡ . | LFS§ . | OS* . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Donor/graft type | ||||||||||||||
| UCB | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| 7/8 BM | 1.12 (0.87-1.45) | N.S. | 1.06 (0.82-1.38) | N.S. | 1.70 (1.16-2.48) | .006 | 6.17 (2.2-17.33)‖ | .0006 | 1.44 (1.03-2.02) | .03 | 2.14 (1.23-3.74)‖ | .007 | 1.07 (0.80-1.44) | N.S. |
| Disease status | ||||||||||||||
| Early | 1 | 1 | — | — | — | — | 1 | — | — | — | — | |||
| Intermediate | 1.20 (1.06-1.37) | .005 | 1.16 (1.01-1.33) | 0.03 | — | — | — | — | 1.22 (1.00-1.49) | .05 | — | — | — | — |
| ATG/alemtuzumab used | ||||||||||||||
| Yes | 1 | 1 | — | — | 1 | — | — | — | — | — | — | |||
| No | 1.24 (1.08-1.42) | .003 | 1.16 (1.01-1.34) | .04 | — | — | 1.57 (1.28-1.91) | <.0001 | — | — | — | — | — | — |
| Recipient race, ethnicity | ||||||||||||||
| White, Non-Hispanic | 1 | 1 | 1 | 1 | — | — | 1 | 1 | ||||||
| White, Hispanic | 1.30 (1.09-1.54) | .003 | 1.37 (1.15-1.63) | .0005 | 1.02 (0.73-1.42) | N.S. | 1.51 (1.17-1.94) | .001 | — | — | 1.12 (0.91-1.37) | N.S. | 1.13 (0.92-1.40) | N.S. |
| Nonwhite, Non-Hispanic | 1.33 (1.13-1.57) | .0008 | 1.38 (1.16-1.64) | .0003 | 1.60 (1.20-2.13) | .001 | 1.42 (1.09-1.85) | .009 | — | — | 1.29 (1.07-1.55) | .009 | 1.39 (1.14-1.68) | .0008 |
| Nonwhite, Hispanic | 2.05 (1.26-3.32) | .004 | 1.63 (0.99-2.69) | .05 | 3.22 (1.69-6.13) | .0004 | 0.55 (0.14-2.22) | N.S. | — | — | 1.71 (0.99-2.95) | N.S. | 1.84 (1.08-3.14) | 0.02 |
| Missing | 1.23 (0.95-1.59) | N.S. | 1.34 (1.03-1.74) | .03 | 0.80 (0.46-1.38) | N.S. | 1.36 (0.90-2.04) | N.S. | — | — | 1.08 (0.80-1.45) | N.S. | 0.99 (0.72-1.35) | N.S. |
| Karnofsky/Lansky score | ||||||||||||||
| <90 | — | — | 1 | — | — | — | — | — | — | 1 | 1 | |||
| ≥90 | — | — | 0.78 (0.65-0.93) | .005 | — | — | — | — | — | — | 0.72 (0.60- 0.86) | .0005 | 0.70 (0.58-0.85) | .0003 |
| Missing | — | — | 0.76 (0.53-1.10) | N.S. | — | — | — | — | — | — | 0.82 (0.55-1.22) | N.S. | 0.82 (0.55- 1.23) | N.S. |
| Donor-recipient CMV status | ||||||||||||||
| −/− | — | — | — | — | 1 | — | — | — | — | 1 | 1 | |||
| −/+ | — | — | — | — | 1.22 (0.96-1.55) | N.S. | — | — | — | — | 1.33 (1.15-1.54) | .0001 | 1.44 (1.23-1.67) | <.0001 |
| Missing | — | — | — | — | 1.81 (0.98-3.33) | N.S. | — | — | — | — | 1.15 (0.71- 1.87) | N.S. | ||
| Year of HCT | ||||||||||||||
| 2000-2003 | 1 | — | — | — | — | — | — | 1 | 1 | 1 | ||||
| 2004-2007 | 0.91 (0.76-1.09) | N.S. | — | — | — | — | — | — | 0.90 (0.69-1.18) | N.S. | 0.85 (0.69-1.03) | N.S. | 0.84 (0.68-1.03) | N.S. |
| 2008-2011 | 0.78 (0.64-0.95) | .012 | — | — | — | — | — | — | 0.79 (0.60-1.03) | N.S. | 0.71 (0.57-0.88) | .002 | 0.71 (0.56-0.89) | .003 |
| 2012-2014 | 1.02 (0.81-1.29) | N.S. | — | — | — | — | — | — | 1.46 (1.08- 1.97) | .014 | 1.11 (0.86- 1.44) | N.S. | 0.97 (0.74-1.28) | N.S. |
| Factor . | GRFS* . | CRFS* . | aGVHD III-IV† . | cGVHD . | Relapse‡ . | LFS§ . | OS* . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Donor/graft type | ||||||||||||||
| UCB | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| 7/8 BM | 1.12 (0.87-1.45) | N.S. | 1.06 (0.82-1.38) | N.S. | 1.70 (1.16-2.48) | .006 | 6.17 (2.2-17.33)‖ | .0006 | 1.44 (1.03-2.02) | .03 | 2.14 (1.23-3.74)‖ | .007 | 1.07 (0.80-1.44) | N.S. |
| Disease status | ||||||||||||||
| Early | 1 | 1 | — | — | — | — | 1 | — | — | — | — | |||
| Intermediate | 1.20 (1.06-1.37) | .005 | 1.16 (1.01-1.33) | 0.03 | — | — | — | — | 1.22 (1.00-1.49) | .05 | — | — | — | — |
| ATG/alemtuzumab used | ||||||||||||||
| Yes | 1 | 1 | — | — | 1 | — | — | — | — | — | — | |||
| No | 1.24 (1.08-1.42) | .003 | 1.16 (1.01-1.34) | .04 | — | — | 1.57 (1.28-1.91) | <.0001 | — | — | — | — | — | — |
| Recipient race, ethnicity | ||||||||||||||
| White, Non-Hispanic | 1 | 1 | 1 | 1 | — | — | 1 | 1 | ||||||
| White, Hispanic | 1.30 (1.09-1.54) | .003 | 1.37 (1.15-1.63) | .0005 | 1.02 (0.73-1.42) | N.S. | 1.51 (1.17-1.94) | .001 | — | — | 1.12 (0.91-1.37) | N.S. | 1.13 (0.92-1.40) | N.S. |
| Nonwhite, Non-Hispanic | 1.33 (1.13-1.57) | .0008 | 1.38 (1.16-1.64) | .0003 | 1.60 (1.20-2.13) | .001 | 1.42 (1.09-1.85) | .009 | — | — | 1.29 (1.07-1.55) | .009 | 1.39 (1.14-1.68) | .0008 |
| Nonwhite, Hispanic | 2.05 (1.26-3.32) | .004 | 1.63 (0.99-2.69) | .05 | 3.22 (1.69-6.13) | .0004 | 0.55 (0.14-2.22) | N.S. | — | — | 1.71 (0.99-2.95) | N.S. | 1.84 (1.08-3.14) | 0.02 |
| Missing | 1.23 (0.95-1.59) | N.S. | 1.34 (1.03-1.74) | .03 | 0.80 (0.46-1.38) | N.S. | 1.36 (0.90-2.04) | N.S. | — | — | 1.08 (0.80-1.45) | N.S. | 0.99 (0.72-1.35) | N.S. |
| Karnofsky/Lansky score | ||||||||||||||
| <90 | — | — | 1 | — | — | — | — | — | — | 1 | 1 | |||
| ≥90 | — | — | 0.78 (0.65-0.93) | .005 | — | — | — | — | — | — | 0.72 (0.60- 0.86) | .0005 | 0.70 (0.58-0.85) | .0003 |
| Missing | — | — | 0.76 (0.53-1.10) | N.S. | — | — | — | — | — | — | 0.82 (0.55-1.22) | N.S. | 0.82 (0.55- 1.23) | N.S. |
| Donor-recipient CMV status | ||||||||||||||
| −/− | — | — | — | — | 1 | — | — | — | — | 1 | 1 | |||
| −/+ | — | — | — | — | 1.22 (0.96-1.55) | N.S. | — | — | — | — | 1.33 (1.15-1.54) | .0001 | 1.44 (1.23-1.67) | <.0001 |
| Missing | — | — | — | — | 1.81 (0.98-3.33) | N.S. | — | — | — | — | 1.15 (0.71- 1.87) | N.S. | ||
| Year of HCT | ||||||||||||||
| 2000-2003 | 1 | — | — | — | — | — | — | 1 | 1 | 1 | ||||
| 2004-2007 | 0.91 (0.76-1.09) | N.S. | — | — | — | — | — | — | 0.90 (0.69-1.18) | N.S. | 0.85 (0.69-1.03) | N.S. | 0.84 (0.68-1.03) | N.S. |
| 2008-2011 | 0.78 (0.64-0.95) | .012 | — | — | — | — | — | — | 0.79 (0.60-1.03) | N.S. | 0.71 (0.57-0.88) | .002 | 0.71 (0.56-0.89) | .003 |
| 2012-2014 | 1.02 (0.81-1.29) | N.S. | — | — | — | — | — | — | 1.46 (1.08- 1.97) | .014 | 1.11 (0.86- 1.44) | N.S. | 0.97 (0.74-1.28) | N.S. |
Bold type denotes values with statistically significant P (<.01).
aGVHD III-IV, grade III-IV aGVHD; N.S., not significant (P > .05); —, not applicable.
Stratified variable: GVHD prophylaxis.
Stratified variable: patient age.
Stratified variables: disease, patient age.
Stratified variables: disease, GVHD prophylaxis.
Beyond 14 months after HCT.